– UK, Oxford – Evox Therapeutics Ltd, a leading exosome therapeutics company, today announced that it has raised £69.2 million in a Series C oversubscribed financing round led by Redmile Group joined by new investors OrbiMed and Invus.
Concurrent with the financing, Chau Khuong, a partner at OrbiMed, will join its Board of Directors.
In addition to Redmile, all existing Series B investors reinvested, including major investors Oxford Sciences Innovation, GV, and Cowen Healthcare Investments.
Eli Lilly, also converted a $10 million convertible note, that formed part of our 2020 collaboration agreement with them, into equity as part of this round.
Proceeds from this financing will support the advancement of Evox’s exosome-based therapeutics pipeline, including the progression of several rare disease assets into the clinic, and the continued development of its world-leading DeliverEXTM exosome drug platform.
“We welcome Chau Khuong to our Board and look forward to his contributions as Evox enters its next phase of growth.” said CEO, Dr Antonin de Fougerolles.
He added: “We are delighted with the support received in this Series C financing from both our existing investors and our new investors. The level of interest in this financing round is a testament to the progress we have made over the last few years. Since our Series B round in 2018, we have continued to develop our DeliverEXTM platform, advance our pipeline of exosome therapeutics, expand our intellectual property portfolio, build our R&D capabilities and bolster our management team. We have also signed significant partnership deals with Eli Lilly and Takeda, two of the world’s leading pharma companies.”
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox uses its proprietary DeliverEXTM technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody, and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.
For more information: https://www.evoxtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
